The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146.
Sujaata Dwadasi
No relevant relationships to disclose
Yan Tong
No relevant relationships to disclose
Tom Walsh
No relevant relationships to disclose
Michael A. Danso
No relevant relationships to disclose
Cynthia X. Ma
No relevant relationships to disclose
Paula Silverman
No relevant relationships to disclose
Mary-Claire King
No relevant relationships to disclose
Susan M. Perkins
No relevant relationships to disclose
Sunil S. Badve
No relevant relationships to disclose
Kathy Miller
Consultant or Advisory Role - Clovis
Research Funding - Clovis